Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers

Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers

Targeted therapies against basal-like breast tumors, which are typically ‘triple-negative breast cancers (TNBCs)’, remain an important unmet clinical need. Somatic TP53 mutations are the most common genetic event in basal-like breast tumors and TNBC. To identify additional drivers and possible drug...

Full description

Bibliographic Details
Main Authors: Adam D. Pfefferle, Yash N. Agrawal, Daniel C. Koboldt, Krishna L. Kanchi, Jason I. Herschkowitz, Elaine R. Mardis, Jeffrey M. Rosen, Charles M. Perou
Format: Article
Language:English
Published: The Company of Biologists 2016-07-01
Series:Disease Models & Mechanisms
Subjects:
Basal-like breast cancer
Exome sequencing
Genetically engineered mouse models
p53
Personalized genomics
Whole-genome sequencing
Online Access:http://dmm.biologists.org/content/9/7/749

Internet

http://dmm.biologists.org/content/9/7/749

Similar Items